COTA

ABOUT COTA

Bringing clarity to cancer

Founded in 2011 by doctors, engineers and data scientists to create clarity from fragmented and often-inaccessible real-world data. COTA curates fit-for-purpose, regulatory-grade oncology RWD from structured and unstructured EHR data that is used across the drug development lifecycle.

Our data is ready for analysis and contains clear longitudinal patients journeys that support regulatory submissions and research questions including treatment patterns, real-world outcomes, and comparisons.

2M+ Cancers live in our network

1,500+ Oncologists across our network

3 FDA and EMA approvals

OUR REAL-WORLD DATA PRODUCTS

1 **FOCUS**
Fit-for-Purpose/
Custom RWD Cohorts

2 **VANTAGE**
Standard-Level
Disease Based RWD

\+ Volume based on disease prevalence and oncology clinical trial enrollment rates in the U.S.

REGULATORY GRADE
COTA RWD in 10+ regulatory filings, including three successful regulatory approvals

UNIQUE DATA MODELS
Data models for each cancer type provide the most clinically relevant data points for that particular disease

DEEP CLINICOGENOMICS
High quality and quantity of clinical and genomics data across solid and liquid cancers

RIGHT SOURCES
50% Academic Networks
50% Community Networks



Geographic representation of patients accessible through our 50/50 mix of academic and community networks

USE CASES

REGULATORY
External control arm support, comparator cohorts

RESEARCH
RWE studies, research publications, scientific innovation, translational epidemiology, early discovery

COMMERCIAL
Comparative effectiveness, HTA

Standard: Data elements defined by our medical team and key industry opinion leaders. Includes demographics, diagnostics, performance status, molecular markers, labs, treatments and outcomes including progression, response, reason for treatment discontinuation, and survival

ONGOING RESEARCH PARTNERSHIPS WITH:

UT Southwestern Medical Center
THE UNIVERSITY OF CHICAGO
FDA
REAGAN-UDALL FOUNDATION for the Food and Drug Administration
FRIENDS of CANCER RESEARCH

LEARN MORE AT: www.cotahealthcare.com